Page 1,278«..1020..1,2771,2781,2791,280..1,2901,300..»

An artist and a transplant researcher discuss the heart – Harvard Gazette

Posted: November 10, 2019 at 9:48 pm

Doris A. Taylors so-called replacement ghost heart suggests something otherworldly, but the eerie-looking form is far from an apparition. Its an innovative approach to organ transplantation that has inspired many in the medical community and at least one artist.

The Texas researchers process piggybacks on natures sophisticated design. Together she and a team of researchers strip cells off human and animal cadaver hearts with a soapy solution, leaving ghostly white protein shells that retain the form of the organ. They inject them with a patients blood or bone-marrow stem cells, and the ghost hearts act as scaffolding on which the newly introduced cells can slowly transform into a beating muscle.

What we said was, Wouldnt it be really cool if we could wash the sick cells out and put the healthy cells back in? said Taylor, director of Regenerative Medicine Research and director of the Center for Cell and Organ Biotechnology at the Texas Heart Institute, during a recent talk at the Radcliffe Institute for Advanced Study.

The hope is that one day these regenerated hearts will resolve the most challenging issues transplant patients currently face: the lack of a permanent artificial replacement, concerns about rejection, and the shortage of viable donor hearts.

Taylors efforts are driving what could become a revolution in organ transplants, and they have sparked the creativity of transdisciplinary artist Dario Robleto, whose latest work, on view at the Johnson-Kulukundis Family Gallery in Radcliffes Byerly Hall, recreates in images and sounds the original pulse wave of the heart first captured in visual form by scientists in the 1900s. Robleto and Taylor, longtime friends and Texas residents, explored those connections during Mondays Radcliffe discussion, which was moderated by Jennifer Roberts, Elizabeth Cary Agassiz Professor of the Humanities.

Robletos exhibit, Unknown and Solitary Seas, touches on the overlap between the medical mysteries and workings of the vascular pump, and the metaphor for the heart as the emotional center of the soul. It includes a video installation that features recreated sounds of a beating heart from the 19th century, reconstructed images of how the earliest pulse waves first appeared on the page, and a series of heart waveform sculptures in brass-plated stainless steel.

Roberts said that with his work, Robleto acknowledges the pulse waves promise, their profundity, their scientific value, but he also reclaims some of their ambiguity and asks us to wonder whether we can or should accept that these waveforms have escaped the realms of art, culture, and emotional communication.

Taylor similarly views her work as a blend of the scientific and the human. It transcends complicated, complex science, she says, in that her ghost hearts require a kind of passion, commitment, care, attention, and nurturing similar to whats required by a small child. Its really about building hearts at the emotional, mental, spiritual, and physical level that I think is going to get them to work, she said.

For Robleto, big ideas, like the creation of a new human heart, require multiple perspectives.

The artist called Taylors work one of the most fascinating and definitely one of the most emotional things Ive ever seen. As an object, he added, the ghost heart is stunningly beautiful but it also raises questions about the self, identity, emotion, the notions of form and where memory is truly held, questions he thinks artists can help address. He cited two of the nations earliest heart transplants, after which the patients wives asked their husbands, who had received donor hearts, if they still loved them.

Taylors work, Robleto said, is right at the edge of identity and materiality and so when the day comes when someone says the first ghost heart transplant I think we will have a similar moment where perhaps we will be forced to re-evaluate what we ask from our heart metaphor.

Dario Robletos Unknown and Solitary Seas is on view in Byerly Halls Johnson-Kulukundis Family Gallery through Jan. 18, 2020.

Follow this link:
An artist and a transplant researcher discuss the heart - Harvard Gazette

Posted in Regenerative Medicine | Comments Off on An artist and a transplant researcher discuss the heart – Harvard Gazette

Micromotors move single cells using magnets and ultrasound – CMU The Tartan Online

Posted: November 10, 2019 at 9:48 pm

A new type of micromotor has been developed. Directed by magnets and powered by ultrasound, these micromotors are capable of traveling across microscopic particles and cells in very crowded areas without causing any damage.

These microswimmers provide a new way to manipulate single particles with precise control and in three dimensions, without having to do special sample preparation, labeling, surface modification, said Joseph Wang, a professor of nanoengineering at University of California San Diego (USCD), in a UCSD press release.

Wang, Thomas Mallouk, a professor of chemistry at the University of Pennsylvania, and Wei Wang, professor of materials science and engineering at Harbin Institute of Technology, are credited as senior authors of a paper detailing the development of these micromotors. The study was published on Oct. 25 in Science Advances.

Researchers tested the technology by moving HeLa cells the oldest and most commonly used cell line for scientific research and silica particles in aqueous media with micromotors. They accomplished this task without damaging nearby particles and cells. In one test, the researchers were able to create letters by pushing particles with the micromotors. In another, they exerted control over the micromotors, making them climb up microscopic blocks and stairs. This test demonstrated that they were capable of navigating over three-dimensional objects.

The micromotors are essentially gold-coated hollow polymer structures that are shaped like a half capsule. Within the body of the micromotor is a tiny magnetic nickel nanoparticle, allowing them to be steered with magnets. The inside surface is treated so it can repel water, so when the micromotor is submerged in water, an air bubble is trapped inside the device. This trapped bubble is integral to the functioning of the micromotor, as it allows the micromotor to respond to ultrasound. Upon receiving ultrasound waves, the trapped bubble begins to oscillate, forming forces that give it an initial push to movement. By applying an external magnetic field, it can move continuously, while altering the direction of the field allows researchers to control the speed and trajectory of the micromotors.

We have a lot of control over the motion, unlike a chemically fueled micromotor that relies on random motion to reach its target, said Fernando Soto, a nanoengineering Ph.D. student studying at UC San Diego. Also, ultrasound and magnets are biocompatible, making this micromotor system attractive for use in biological applications.

The authors plan on making improvements to the micromotors in the coming years. For example, they want to make them more biocompatible using biodegradable polymers and a magnetic material that is less toxic, such as iron oxide. Thanks to this technology, the researchers have opened new possibilities for nanomedicine, tissue engineering, targeted drug delivery, regenerative medicine, and other applications in the field of biochemistry.

See original here:
Micromotors move single cells using magnets and ultrasound - CMU The Tartan Online

Posted in Regenerative Medicine | Comments Off on Micromotors move single cells using magnets and ultrasound – CMU The Tartan Online

Specialty MED Launches Online Training Course for Regenerative Hair Regrowth Combination Therapy Protocols for Cellular Hair Regrowth – PR Web

Posted: November 10, 2019 at 9:48 pm

I cant stress enough the value of having the Specialty Med Training team work with me, side by side, teaching me specific techniques, proven protocols and pearls of how to successfully implement them into my practice offering... Elvira Wright, SMT Client

DELRAY BEACH, Fla. (PRWEB) November 08, 2019

Specialty Med Training, one of the nations largest training, research and marketing company has added a combination cellular hair regrowth course to its extensive library of regenerative medicine educational programs. This latest course, designed to instruct and certify practitioners on how to combine regenerative therapies including platelet rich plasma (PRP), micro-needling, pharmaceutical peptides, photobiomodulation, and nutraceuticals for cellular hair regrowth. The comprehensive course is offered as an online video demonstrated course broken into three modules or trainees have the option for a clinical educator to travel to the clinic to teach the doctor and the staff how to successful perform and implement the therapies into their practice offering.

I cant stress enough the value of having the Specialty Med Training team work with me, side by side, teaching me specific techniques, proven protocols and pearls of how to successfully implement them into my practice offering. The best part- I didnt have to leave my office, my schedule was not disrupted and Im certain I cut the learning curve in half! Elvira Wright, SMT Client

Attendees with gain a full understanding of the pathophysiology of hair loss, the most common causes, as well as other less common causes for hair loss and hair thinning. The course covers the history of the therapies, mechanism of action, review of articles published, and even how to talk to your patients and staff. The video portion demonstrates each therapy in the combination protocol in great detail.

In addition to understanding how to prep patients, process biologics and apply these therapies by watching live procedures on actual patients, Specialty MED training registrants will receive all the tools necessary to successfully implement regenerative procedures into their clinical practice quickly and efficiently.

The training courses are intended for all practitioners; those with no experience using regenerative therapies to those with significant experience. Upon final completion of the online course, graduates will be certified by Specialty MED Training.

Training program fees range from $599 - $3,995.

To register for training, visit specialtymedtraining.com or call 561-408-7248.

About Specialty Med TrainingSpecialty MED Training (SMT) is a national training, research and marketing company; dedicated to helping physicians bring the latest regenerative therapies and treatment options to their patients. They are actively building a national network of leading providers committed to the ethical and responsible advancement of the use of regenerative therapies in clinical practice.

Share article on social media or email:

More:
Specialty MED Launches Online Training Course for Regenerative Hair Regrowth Combination Therapy Protocols for Cellular Hair Regrowth - PR Web

Posted in Regenerative Medicine | Comments Off on Specialty MED Launches Online Training Course for Regenerative Hair Regrowth Combination Therapy Protocols for Cellular Hair Regrowth – PR Web

Cucalorus Connect Conference Nov. 14-15 explores intersection of creativity and technology – WRAL Tech Wire

Posted: November 10, 2019 at 9:48 pm

WILMINGTON Cucalorus Connect, held Nov. 14 and 15 in Wilmington, explores the intersection between creativity, technology, and humanity, this year with a different structure and emphasis on innovative healthcare technology.

The two-day gathering brings people together to discuss what kind of future we could build if we use innovation and technology to expand our sense of humanity. The conference features leading thinkers on health, finance, startups, coastal resilience, racial justice.

This year says Dan Brawley, director of Cucalorus, the structure of the event has changed. Its more holistic and less compartmentalized. As it evolved, weve gotten more clear about the type of experience we wanted to create for people.

Dan Brawley, director of Cucalorus. Photo by R Wright.

Though it began as primarily a business conference, It isnt just a conference about how to make money, Brawley said. Its a conference about how to make the world a better place using technology and creativity.

Nick Adkins, co-founder of Pinksocks Life, a nonprofit organization focused on promoting human connection around the world, will deliver the keynote address on The Power of Connection

The pinksocks movement empowers people from all walks of life to connect with anyone, anywhere, by creating a global tribe of pinksocks-wearing people who are focused on empathy, caring and love. The movement has been decommoditized from its beginning in 2015 all pinksocks are gifts. Every connection made between the gift giver and recipient is based on an authentic connection, not a transaction.

Pinksocks movement founder Nick Adkins keynotes Cucalorus Connect this year. Photo courtesy of Cucalorus.

There is a lot of focus in the program on the future of healthcare with an emphasis on helping people discover new ways to use innovation and technology. How mind-bending it is that you can improve your health in ways we never imagined, said Brawley.

One of the sessions Brawley finds most interesting is Marie Johnsons Digital Humans in Healthcare. Johnson will talk about what she sees as her moon shot, where digital humans are part of an augmented health ecosystem: helping patients and reducing staff burnout.

The digital avatars talk to you all the time and have to be real and authentic, notes Brawley. Its challenging, he said, Ten times harder than making a movie.

Johnson, an Australian entrepreneur, conceived and led the global co-design effort with people with disabilities to deliver Nadia the first AI digital human for service delivery. This work sparked a global industry and appetite for AI-powered digital humans.

An AI Digital Human Cardiac Coach is Johnsons current effort. Its day to day indicators may even be able to predict when a patient will suffer a heart attack. Its a wildly creative app that promises to change things, Brawley said. Some of the most creative people in the world are computer programmers. The things they do with ones and zeroes are incredible.

Film explores regenerative medicine

Other health-focused sessions include Regenerative Medicine in the film Five Minutes. Five Minutes is a film about Baptiste Touissants recovery when a suicide bomber detonated only feet from him in Afghanistan and his hope for regenerative medicine (RM) for U.S. soldiers.

RM promises a future where doctors, using a soldiers own cells, rebuild genitalia and reconstruct arms and legs blown apart by shrapnel. The animated narrative film is a five-year effort directed, produced and edited by Wake Forest University faculty. Wake Forest is a leader in RM research.

More Than Words: how visuals can help us heal healthcare, examines how words alone cant efficiently explain bodily sensations or lifetime journeys. They cant sufficiently show emotions or trauma. As a result, patients and doctors often dont understand each other, and our broken healthcare system bumbles along. This session will feature stories from a doctor and a patient who have each discovered new ways of communicating using visuals and drawing.

Apart from the healthcare focus, one of the most interesting sessions is Youre in the matrix and just dont know it. Two University of North Carolina at Wilmington professors discuss the possibility that we may all be living in the paradigm developed in The Matrix movie franchise.

Dr. Curry Guinn and Dr. Julian Keith, UNCW professors, will discuss the possibility that were in the matrix and dont know it. Photo by R Wright.

The conference does still cover hot business topics, from the Influence of Design, to Martech. Martech is the latest buzzword in the marketing industry. It refers to any technology that a marketer can use to reach a potential customerfrom social media scheduling platforms to email.

Thesession highlights how to use Martech in all phases of marketing and PR campaigns from strategic planning to implementation and results measurement with the goal to create efficient and effective campaigns.

Another session looks at Blockchain technology, contrasting whats hot vs. whats hype.

Image courtesy of Cucalorus

The 10X10 Challenge returns this year. Ten entrepreneurs are paired with 10 filmmakers and challenged to make a three-minute promo video in five days. The films are shown on Sunday. The Rocket Pitch event is a fast-paced pitch competition. startups go head-to-head with just 90 seconds and one slide to capture audience votes.

BarMembership

Brandon Noel

An all-in-one solution compliance platform for North Carolina bars to manage members.

GreenStream Technologies

Karen Lindquist

Monitors and reports conditions in the environment with an end-to-end solution for floods in urban, suburban, rural and even remote environments.

Language Corpus

Reid Wilson

A subscription-based offering for intermediate and advanced language learners to understand what people are saying to them, around them and about them.

Survei

David Stone

Apartment complexes share what is known as a competitive portfolio. Survei speeds up the process, while also increasing data reliability.

Safe and Sound

Elizabeth Baker, Stacey Kolomer

A disaster management mobile app which informs managers of colleagues locations in a crisis, while maintaining security and privacy for a healthy work/life balance not given when using social media.

Skilly-do

Claire Holroyd

A toolkit proven in the real world with thousands of teachers and children to make the most of childs early development and learning through play.

See the 10X20 and Rocket pitch session description for links to the companies.

Read the original:
Cucalorus Connect Conference Nov. 14-15 explores intersection of creativity and technology - WRAL Tech Wire

Posted in Regenerative Medicine | Comments Off on Cucalorus Connect Conference Nov. 14-15 explores intersection of creativity and technology – WRAL Tech Wire

RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare -…

Posted: November 10, 2019 at 9:48 pm

HAIFA, Israel, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the RESTORE Consortium is hosting its 1st Advanced Therapies Science Meeting (ATSM), which is being held November 25-26, 2019 in Berlin. As a leading member of the large-scale research initiative, Pluristem, along with additional respected members, is committed to accelerating the availability of advanced therapies to all those in need, a main motivation standing behind RESTORE.

Led by Charit-Universittsmedizin Berlin, and coordinated by Professor Hans-Dieter Volk from the BIH-Center for Regenerative Therapies in Berlin, RESTORE aims to promote groundbreaking research, drive Europe to the forefront in advanced therapies and deliver a pipeline of potentially transformative cures to patients in need. Advanced Therapies are a potential game changer in health care, aiming to shift our focus from chronic treatment of disease to regeneration of health, said Prof. Volk. We are determined to translate promising research findings into safe therapies, and we are working across disciplines and national borders in order to achieve this goal. The 1st Advanced Therapies Science Meeting provides the opportunity to discuss the still numerous obstacles in the way of implementing these promising therapies in routine clinical care.

This initiative may hold the key for changing the approach towards medicine in Europe, and advancing solutions for patients in need, said Zami Aberman, Executive Chairman of Pluristem. The European Commission is poised to make a significant investment of up to 1 billion in a consortium of companies that can drive forward the development of novel regenerative therapies, and we are pleased to be a leading part in this effort. Given our proprietary cell manufacturing technology and broad, late-stage pipeline, we believe we can play a key role toward making the transforming promise of advanced therapies into a reality.

The 1st ATSM will bring together experts from industry, patient organizations and academia to discuss the challenges within the field of advanced therapies, which include gene and cell therapies and tissue-engineering approaches. The ATSM is focused on trying to drive forward a concerted interdisciplinary effort, making use of science, infrastructure and funding within Europe to make regenerative therapies available to the broadest possible patient population.

The two-day program will include talks from Nobel Prize winner Ada Yonath (Director of Weizmann Institute of Science, Israel), Michele De Luca (University of Modena, Italy), Timothy OBrien (National University of Ireland, Galway, Ireland), Maksim Mamonkin (Baylor College of Medicine, USA), Manuela Gomes (University of Minho, Portugal) and others.

RESTORE partners include the Charit Universittsmedizin Berlin and Berlin Institute of Health (Germany), the University of Zurich (Switzerland), Cell and Gene Therapy Catapult (United Kingdom), TissUse GmbH (Germany), Pluristem (Israel), Miltenyi Biotec GmbH (Germany), INSERM Institut National de la Sant et de la Recherche (France), Innovation Acta S.r.l. (Italy), Fondazione Telethon Milan (Italy), and the University of Minho (Portugal).

About Pluristem TherapeuticsPluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.

Story continues

Safe Harbor StatementThis press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluristem is using forward-looking statements when it discusses the potential for the RESTORE Consortium to receive up to a 1 billion award by the European Commission and the timing of the potential award, that RESTOREs aim is to promote groundbreaking research, drive Europe to the forefront in advanced therapies and deliver a pipeline of potentially transformative cures to patients in need, that RESTORE and the 1st ATSM may hold the key for changing the approach towards medicine in Europe, and advancing solutions for patients in need, and its belief that given its proprietary cell manufacturing technology and broad, late-stage pipeline, it believes it can play a key role toward making the transforming promise of advanced therapies into a reality. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; Pluristem may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Pluristems products may not be approved by regulatory agencies, Pluristems technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Pluristem may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Pluristems process; Pluristems products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Pluristems patents may not be sufficient; Pluristems products may harm recipients; changes in legislation may adversely impact Pluristem; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

See more here:
RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare -...

Posted in Regenerative Medicine | Comments Off on RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare -…

Working hand in hand with the nation’s largest integrated care system | Penn Today – Penn: Office of University Communications

Posted: November 10, 2019 at 9:47 pm

The Veterans Administration has traditionally been an incubator for innovations that improve quality of life not only for veterans but also for civilian populations around the worldideas like bar-coding machines, or the discovery that daily aspirin cuts the rate of heart attacks for certain patient populations. For many years and in a range of capacities, Penns School of Nursing has been a close VA collaborator.

In 2011,for example, in addition to her role at Penn, palliative care professor Mary Ersek became director of the Veteran Experience Center, a national quality-improvement initiative housed at Philadelphias Corporal Michael J. Crescenz VA Medical Center. Rosemary Polomano, Penn Nursings associate dean for practice and a professor of pain practice, helped change the standard pain scale employed by the VA.

There are many examples of this partnership, with innovative solutions aimed at the largest integrated health system in the U.S. and the top employer of nurse practitioners, according to the Veterans Health Administration. Along the way, the VA has also built systems for tracking outcomes, leading to a treasure trove of data.

Its a great time for evidence-based research and training, saysCoy Smith, associate director of patient care services and nurse executive at the Philadelphia VA, as well as assistant dean for clinical practice at Penn Nursing. A lot of this work is transferrable to non-VA patients.

Here, a look at the work made possible because of the Veterans Health Administration-Penn Nursing collaboration.

Evidence-based health care practices are interventions based on the best, latest scientific findings. Penn sleep and health behavior researcher Amy Sawyer is currently leading 15 evidence-based quality improvement projects at the Philadelphia VA, on subjects like preventing injury in surgical patients and secondary traumatic stress in health care providers.

Change, no matter how you look at it, is hard, Sawyer says. Its hard to accept, and its hard to convey to others that change needs to happen. But implementing it can have real results, like with a recent occupational health project that involved switching the type of tuberculosis testing the VA used for incoming employees.

Unlike the standard test, called purified protein derivative or PPD, a newer test called T-SPOT.TB does not require a follow-up visit after 48 to 72 hours. During a PPD shortage two years ago, VA clinicians put in place the T-SPOT.TB procedure and followed it for a year. The program has since rolled out across the entire VA system, leading to a 29% increase in employee compliance, a 40% drop in costs, and a 50% reduction in time to clear new hires.

We used to think of quality improvement and research as separate, Ersek says. But over the years weve gotten more sophisticated. We use research methods. We sort of mimic, statistically, a randomized control trial.

To that end, Ersek and her team use the Bereaved Family Survey (BFS) in their VA work. The BFS, developed through a VA-funded research project and now used throughout the system, asks respondents to evaluate quality of care at the end of life. Its mailed to the next of kin of every veteran who dies at a VA facility or in one of several VA home-based primary care programs. Facility-level scores are calculated quarterly and sent to each facility. The Veteran Experience Center also works directly with care teams to help them interpret their scores and develop strategies to improve care and outcomes.

For example, we might identify chronically low scores on an overall item, as well as those related to communication for a specific facility, Ersek says. Training in family conferences might then follow. We continue to monitor their BFS scores during and following the training to see whether it had an impact on outcomes, she adds.

The survey is a unique way to keep a pulse on the quality of care at the VA for veterans and families, saysAnn Kutney-Lee, an adjunct associate professor of nursing who studies the effects of nursing care organizations on patient outcomes. We ask about communication with providers, whether their preferences were met for treatment, she says. We ask about emotional and spiritual support. Did they get the amount of support they wanted? Did they see a chaplain if they wanted one?

Veteran demographics are shifting from those who served in World War II and the Korean War to those who served in Vietnam. This has implications for end-of-life care, as veterans from the Vietnam era are more likely to have been exposed to dangerous combat situations, says Kutney-Lee. Many veterans were fighting in jungles and mountains; there were hidden explosives planted, all with a near-constant threat of being ambushed, she says. The nature of the direct combat situations was very different.

The way society welcomed them home was different, too. World War II vets were hailed as heroes, enjoying national support. Vietnam vets experienced the opposite, says Kutney-Lee. Things were thrown at them when they got off the planes. Today, they are less willing to talk about their experiences, something that can resurface, emotionally, at the end of life.

Its something Kutney-Lee and colleagues are trying to understand to better prepare health care providers to treat these vets. They are seeing higher rates of anxiety and post-traumatic stress, as well as more chronic illnesses that correlate with chemicals such as 2,4,5-T, an ingredient in the herbicide Agent Orange, to which many soldiers in Vietnam were exposed. In an effort to be proactive, the VAs Hospice and Palliative Care Program Office and the Veteran Experience Center are using the BFS and other data to create educational programs aimed at helping providers meet this groups unique end-of-life needs. We want the vets and their families experience to be as peaceful as possible, Kutney-Lee says.

She is involved in another project with Ersek andMargo Brooks Carthon, another Penn Nursing researcher, to study racial and ethnic disparities in quality end-of-life care for vets. Some of their work has found that the next of kin of African American vets were 50% less likely than other groups to report that their loved ones received excellent care at the end of life. The researchers want to know why.

One clue: Members of racial and ethnic minorities tend to be more sensitive to changes in nurse-staffing levels. The researchers hypothesize that in facilities where staffing is better, nurses are better positioned to meet the complex care needs of patients, which may also apply at the end of life. They have the resources they need and the time to spend with their patients, says Kutney-Lee.

Pain management entails a complex matrix of mind and body, which makes having a standard scale on which to measure pain crucial.

Penn Nursings Rosemary Polomano specializes in managing acute pain following combat-related injuries. After learning that clinicians in 28 facilities who used the standard numeric pain rating scale (0-10) found it inadequate to help patients and health care providers communicate about pain-intensity levels, Polomano collaborated with leaders from the Defense and Veterans Center for Integrative Pain Management and others to develop the Defense and Veterans Pain Rating Scale (DVPRS).

The scale integrates word anchors (from no pain to as bad as it could be, nothing else matters) with color-coding and facial expressions to help patients rate their pain.

According to Polomano, DVPRS is now the official military pain scale, with the goal of being used in all Department of Defense health care facilities. Other health systems are free to use it too, Polomano says. It is in the public domain.

Polomano also teachesPain Science and Practice, a class open to students from Penn Nursing, Penn Dental, and Penns Perelman School of Medicine. This year, in partnership with the Uniformed Services University Graduate School of Nursing in Bethesda, Maryland, 30 active-duty military personnel from their nurse anesthesia program attended the class.

Nurses work at the heart of the changes in veterans care and, therefore, help to shape the future of American health care. Much of the VAs innovative models of care delivery are due to the leadership and contributions of VA nurses, says David Shulkin, a Distinguished Health Policy Fellow at Penns Leonard Davis Institute of Health Economics and a former secretary of veterans affairs. Its often their affiliation with leading academic centers like Penn that help to ensure the VA remains at the forefront of these innovations.

Ive often felt that the VA is the best place for advanced practice nurses, saysPatricia DAntonio, the Carol E. Ware Professor in Mental Health Nursing and director of the Barbara Bates Center for the Study of the History of Nursing. One of the best jobs she says she ever had was working with VA nurses to identify and help patients with compelling emotional or psychological needs. One patient, an outgoing, lovable former boxer, would sometimes lash out and punch someone when he got upset. The VA nurses developed a plan to appoint him an unofficial nursing assistant. He followed a nurse around, carried water, etc. He had a job to do, says DAntonio. With a new sense of purpose, he could control his anger. No more punching.

Ersek was similarly drawn to the VAs work. Being involved in the military, thats a big honor. Our mission as care providers is not about prestige, she says. We get to use rigorous research methods, but I like that we stop and say its not just an academic exercise; its about using these advanced analytic methods to improve care for veterans.

That sense of purpose goes a long way. I havent practiced clinically at the VA since 1992, says DAntonio, but I still describe myself as a VA nurse. Its part of my identity. Thats true for many among the ranks of Penn Nursing faculty, who work hand in hand with the nations largest integrated care system treating a unique patient population thats changing every day.

A longer version of this feature, by Louis Greenstein, originally ran in the Spring 2019 issue of the Penn Nursing Magazine.

Read this article:
Working hand in hand with the nation's largest integrated care system | Penn Today - Penn: Office of University Communications

Posted in Integrative Medicine | Comments Off on Working hand in hand with the nation’s largest integrated care system | Penn Today – Penn: Office of University Communications

Medical doctors will soon rally traditional medicine for integrative treatment of ailments – Guardian

Posted: November 10, 2019 at 9:47 pm

Recently, World Health Organisation (WHO) pledged support to the federal government to integrate traditional medicine into national healthcare, what is your take on this?That is hugely awesome and no doubt it is an encouragement for practitioners of traditional medicine that the days of more honour and recognition for our practice is here. As it is said, the future is here. With this kind of support from the global apex health body, it further goes to show that the world knows and confirms that indeed nature cures. Of course, this is not the first time we would be telling the masses that nature has cure for all that affects our body, but this kind of recognition speaks volume to the wide acceptability of our call. In no time, we would begin to see even medical doctors rallying around traditional medicine for integrative treatment for ailments just as we have seen in other climes where the practice of natural medicine has been more established and controlled. Even as natural therapies continues to bask in the glory of its richness and wellness as an efficient cure system, this kind of support at this time in our country is needed to harness all the potentials. We look forward to seeing in practice and learning of this healthcare system, which we believe will fight against incompetence and lack of best practice that ravages the traditional medicine.

What is the likely outcome of this synergy?If by this you mean the synergy the integration of traditional medicine into the healthcare system will birth, then one thing I would say is, let us look at the Chinese and the Indians. What did the synergy foster for them? A sustainable healthcare system, assured healthy living and a population living more hale and hearty. This is because with traditional medicine and implementation of best practice which is a function of structured learning, just as we have for the orthodox medicine, will not just treat the surface of ailments or treat the effects of diseases, rather traditional medicine will imbibe the very message of natural treatment therapies which is to treat the root cause of every diseases and create true cure for the body. As abundantly blessed as the Nigeria has been blessed with almost all kinds of herbal and other traditional medicine therapies, we are yet to harness this into both health wellness and economic growth. The reason for this being that there are a lot of quacks in the practice of traditional medicines.

But with a synergy like this, it will bring forth more standard which will enable us to sieve the shaft away from the substance, making the business of health primarily based not on making money but that of saving lives and empathising with those with ailments of different kinds. Lastly, with a synergy like this, we would find standards in our traditional healthcare management system just as I saw in my recent travel to Malaysia for an International Course on Neuroacupuncture and Non Invasive Pain and Paralysis Management.

How do you think traditional medicine can fit into healthcare?Traditional medicine, which is primarily about utilising nature in the process of administering cure, is synonymous to effective healthcare just as life is synonymous to living. Any healthcare system that is yet to embrace traditional medicine as a mode of treatment is not only lagging behind, it is almost nonexistent because the very basis upon which living is formed, that is nature, has been neglected. I remembered when I was learning at the Indian Board of Alternative Medicine where I first bagged my Doctor of Natural Medicine after having graduated from University of Ilorin as a first degree holder in Biochemistry, my learning made it clear that even the synthetic drugs used in curing humans has a greater element of natural cure in it. Why then would someone not want to go to natural cure through expert guidance and make-up to cure that which affects the body.

You have had success in treating patients with chronic and severe pain within few minutes, what can you say about this?We as doctors are only applying treatment protocols with best practice, we cannot totally lay claims to our knowledge and practice as the basis for the success. God Almighty cures and no doubt about that. But then as humanly possible, yes, it is true that I am having success in treating chronic pain related ailments such as sciatica, paralysis patients and so on and within minutes, my patient experience instant relief from pains they have suffered in years. In fact, my teacher that taught me this treatment system would treat over 200 patients in a day when I was learning with him. These are patients with different chronic pain and paralysis related health issues. So, the treatment methodology I employed is Non-Invasive Neuroacupuncture which I learnt during my last learning tour to Kuala Lumpur, Malaysia. One thing I am passionate about is to continue to research and learn the best and less troubling ways to bring smile to the faces of my patients. This is why aside from putting a lot of efforts into research; I have interest in continuous learning which has made me travel to Colombo, Sri-Lanka where I bagged my Doctor of Medicine in Acupuncture. Still, I am not stopping. My aim is also to bridge calibre in Traditional African and Chinese Medicine to give pristine admiration to natural healing.

How does neuro acupuncture work? Arent there side effects of this therapy?No. Neuroacupuncture is a very good treatment procedure with no known side effects. This treatment is based on knowledge of traditional acupuncture and neurology. It is done by inserting acupuncture needles into loose areolar tissue layer of the scalp to stimulate the brain neurons of the underlying area. Since the skull protects the brain and there are no organs in the scalp to injure it is a very safe treatment. Its a non-invasive procedure and works by stimulating the brain cells that are related to the impaired functions. The mechanism is three-fold: to wake-up the brain cells that are not dead but lacking in proper functioning, to encourage the recruitment of healthy brain cells to perform the lost function and to promote a healthy reintegration of the brain system. It does not only treats pains but also paralysis, Parkinsons Disease, multiple sclerosis, traumatic brain injury, spinal cord injury, motor neuron diseases, Alzheimers disease, restless leg syndrome and attention deficit hyperactivity disorder and other neurological issues. Scalp acupuncture can help regain speech in all kinds of Aphasia: expressive, receptive, anomic or global. The speed and amount of recovery vary with the individual and the severity of damage but progress is usually readily seen within few minutes of treatment.

You treat people with cancer and other chronic diseases, is it only acupuncture that you are using or there is another treatment method you are adopting?First thing I will say here to clarify the misconceptions that there are some incurable diseases is that which I have said in past interviews. I as a person do not believe there are incurable diseases, but I know for sure that there may be incurable cases. So this has influenced my belief and interest in always researching on how we can improve on treatment because people are out there in pains and need healing. Why then would we not as practitioners continue to make research on how to improve the wellness of the people. So going back to the question, no, it is not Acupuncture alone that we use as the treatment protocol. We utilise a system called integrative system that allows us to use different therapies in treating our cancer patients. But then Acupuncture is an integral part of that protocol because it helps us manage pain for our cancer patients. We integrate different therapies in order to achieve success as early as possible. Our local herbs and spices play major role in treating these conditions, also, massage, diet and nutrition therapies. I combine as many therapies as possible. For cancer, up-to seven therapies will be combined depending on the type of cancer. I hold that not any therapy is self-sufficient. Every therapy has its own limitations. Combining them will bring meaningful results and may lead to cure in maturation of time.

Visit to your centre shows some children affected by Autism recovering fast, how do you manage to achieve this?Yes, we have really worked on autism and sincerely I would say that we can assist autistic children get better. We have been successful in about three cases and many more successes are approaching by Gods grace. The major treatment methods are herbalism and neuro acupuncture. Also, administration of Camels milk, black seed and natural honey have really been effective in alleviating the symptoms associated with autistic especially speech difficulty and walking. We appeal that the WHO and FG continue looking into traditional medicine. No doubt, there is a need for integrative medicine in order to achieve better results.

You have treated many HIV patients, but not many are too keen to face the media due to the stigma attached to it, what are you doing differently?Should I say its not curable so that I wont get held? Well, let me simply say the truth. There is no diseases that isnt curable if given integrative natural approach and enough treatment durations. HIV is one of the easiest diseases to treat but unfortunately many still believe its cure is just a claim. There are natural herbs and spices that get rid of this virus in the body within few months, no doubt. Some of what I use are garlic, Indian costus and black seed. They are very potent and give good result if taken for many months. How to prepare, required dose and dosages for different individuals is key and thats where I come in.

More:
Medical doctors will soon rally traditional medicine for integrative treatment of ailments - Guardian

Posted in Integrative Medicine | Comments Off on Medical doctors will soon rally traditional medicine for integrative treatment of ailments – Guardian

MD Anderson Partners with Takeda to Develop CAR Natural Killer-Cell Therapy – Cancer Network

Posted: November 9, 2019 at 11:48 am

The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited have entered an exclusive license agreement and research agreement to develop and market chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies.

Under the agreement, Takeda will receive access to MD Andersons treatment platform in order to develop and commercialize the CAR NK-cell therapies for up to 4 programs, according to the announcement made Tuesday.

With their expertise in hematologic malignancies and commitment to developing next-generation cell therapies, Takeda is the ideal collaborator to help our team advance CAR NK-cell therapies to patients in need of treatments, said Katy Rezvani, MD, PhD, a professor of stem cell transplantation and cellular therapy at MD Anderson.

The therapy has a similar strategy to the much-touted CAR T-cell therapy, which shows major promise in many cancers, by collecting certain white blood cells of patients, arming them with targeted surface receptors to battle the subjects particular cancer, and then infusing them back into the patients blood.

However, chemotherapy may leave some patients without sufficient autologous T cells in their blood for treatment with CAR T-cell therapy, while others may not have the time that is required for a laboratory to generate enough T cells, according to the researchers.

CAR NK-cell therapy, developed at MD Anderson, uses natural killer cells from cord blood. The team has said that it allows production of a therapy that doesnt have to be tailored for each and every patientand also obviates the possibility of graft-versus host disease, which is a danger with some T-cell varieties.

The MD Anderson team used a retrovirus to introduce new genes into the NK cells: CD19 is added to increase the CAR NK specificity for B-cell malignancies; interleukin 15 (IL15) is added to prolong the present of the cells in the body; and a CASP9-based suicide gene as a kind of safety measure, which can be activated to trigger apoptosis by small-molecule dimerizers if there is toxicity after infusion.

In announcing the agreement, MD Anderson and Takeda emphasized that the off-the-shelf CAR NK treatment could be administered at outpatient locations.

So far, the treatment has proven safe: An ongoing phase I/2a clinical study in patients with relapsed and refractory B-cell malignancies showed that the CD19 CAR NK-therapy has not been associated with the severe cytokine release syndrome or neurotoxicity observed with existing CAR-T therapies.

Takeda said they plan to initiate a pivotal study of the CD19 CAR NK-cell therapy in 2021.

MD Anderson receives an upfront payment that was unspecified by the parties as part of the deal, as well as tiered royalties on eventual net sales, according to the statement.

Rezvani said the goal is to make therapies that get to patients and ultimately change lives.

Our vision is to improve upon existing treatments by developing armored CAR NKs that could be administered off-the-shelf in an outpatient settingenabling more patients to be treated effectively, quickly, and with minimal toxicities, said Rezvani.

Original post:
MD Anderson Partners with Takeda to Develop CAR Natural Killer-Cell Therapy - Cancer Network

Posted in Cell Therapy | Comments Off on MD Anderson Partners with Takeda to Develop CAR Natural Killer-Cell Therapy – Cancer Network

Takeda, Anderson Cancer Center team up for cell therapy – BSA bureau

Posted: November 9, 2019 at 11:48 am

Takeda and Anderson Cancer Center announce cooperation to accelerate the development of clinical stage, out-of-the-box CAR NK cell therapy platform

University of Texas MD Anderson Cancer Center(The University of Texas MD Anderson Cancer Center)and Takeda Pharmaceutical Company Limited (Takeda Pharmaceutical hasannounced an exclusive licensing agreement and research agreement to develop cord blood-derived chimeric antigen receptors for "arming" IL-15 for the treatment of B-cell malignancies and other cancers Chimeric Antigen Receptor-directed Natural Killer (CAR NK) cell therapy.

Under the agreement, Takeda will receive access to the CAR NK platform of the Anderson Cancer Center and the exclusive rights to develop and commercialize up to four projects, including a CD19-targeted CAR NK cell therapy and a B-cell maturation. The antigen (BCMA) is the target of CAR NK cell therapy.The Takeda and Anderson Cancer Center will conduct a research collaboration to further develop the above CAR NK project.

Katy Rezvani, MD, Ph.D.,Professor ofStem Cell Transplantation and Cell Therapyat theAnderson Cancer Center,said: "Our vision is to improve existing treatments by developing armored CAR NK, which can be administered in outpatient settings. Out of the box, more patients can get effective, fast and least toxic treatment. Takeda's expertise in hematological malignancies and the commitment to develop next-generation cell therapies make it an ideal partner for our team. Promote CAR NK cell therapy for patients with therapeutic needs."

New ways to deliver out of the box ready to use CAR in outpatient facilitiesallogeneic Anderson Cancer Center platform CAR NK NK cells isolated from umbilical cord blood, the fight against certain cancers expressing CAR targets after processing.CAR NK cells are modified by retroviral vectors to deliver genes and enhance their efficacy against specific tumors.CD19 CAR increases the specificity of these cells against B cell malignancies, while the immune cytokine IL-15 enhances the proliferation and survival of CAR NK cells in vivo.

Existing CAR T cell therapy drugs use patient-generated genetically modified T cells, and the preparation process takes several weeks. In contrast, CAR NK cells are designed to be prepared from non-relative donor sources and stored in an out-of-the-box manner. So that treatment can be implemented faster.

CD19 CAR NK cell therapy is expected to be administered in an outpatient setting.In an ongoing phase 1/2a clinical study, patients with relapsed refractory B-cell malignancies who received CD19 CAR NK cell therapy did not see severe cytokine release syndrome (CRS) observed in existing CAR-T treatments. ) or neurotoxicity.

Anderson Cancer Center to develop CAR NK platform led by Dr. Rezvani, and withadoptive cell therapy platform,Chronic Lymphocytic Leukemia Moon ShotandB-the Cell Lymphoma Moon Shotfurther support of the project were the hospitalMoon Shots Programof In part, the project is a collaborative effort to rapidly develop scientific discoveries into meaningful clinical advances that can save patients' lives.

Takeda: CAR accelerate the development of next-generation multiple platformsAndy Plump Takeda, president of R & D, MD, Ph.D., said: "Anderson Cancer Center CAR NK cell therapy platform represents a potential cure for the drug, which is what we are to CD19 CAR NK Established as a leader in the treatment of drug candidates for cancer in the field. We must work flexibly and purposefully, so we plan to start the pivotal study of CD19 CAR NK in 2021."

In addition to CAR NK cell therapy, Takeda and its partners are investigating ways to improve the safety, efficacy, and accessibility of first-generation CAR T cell therapies, includinggamma delta CAR T,induced pluripotent stem cell-derived CAR T,with solid tumors as targets of CAR Tandother next-generation methods.Takeda plans to the end of fiscal year 2020 to promote the five kinds of tumor cell therapy to clinical stage.The platform is being developed through collaboration with partners and the use of Takeda's expertise in transforming cell therapy engines that provide bioengineering, chemistry, manufacturing and control (CMC), clinical and transformation functions in a single location to overcome cell therapy drugs. Numerous manufacturing challenges in development.

Takeda is responsible for the development, manufacture and commercialization of the CAR NK products produced by the agreement.The Anderson Cancer Center will receive upfront payments and be eligible to receive royalties for development and commercialization milestones for each target and for any CAR NK product net sales.

The Anderson Cancer Center and Takeda will continue to conduct research on other targets and the CAR NK platform under the direction of a joint research committee.The Anderson Cancer Center will deploy aninstitutional conflict of interest management and monitoring programfor the study.

Read the rest here:
Takeda, Anderson Cancer Center team up for cell therapy - BSA bureau

Posted in Cell Therapy | Comments Off on Takeda, Anderson Cancer Center team up for cell therapy – BSA bureau

New cell therapy player launches with $57M from marquee investors to go after ‘definitive’ tumor targets – Endpoints News

Posted: November 9, 2019 at 11:48 am

A crew of Amgen and Kite vets is publicly throwing their new startup into the cell therapy hat though they are saying little outside of the basics and $57 million in Series A cash.

The Column Group, Vida Ventures, Samsara BioCapital and Nextech Invest are backing A2 Biotherapeutics quest to find new ways of engaging immune cells in selectively attacking cancer. To do so, the biotech is working with two target classes: peptide MHC targets and targets that are irreversibly lost in tumor cells. The former builds on an increasingly popular strategy of locating neoantigens for T cells to home in on, while the latter is inspired by a mechanism used by natural killer cells.

A2 Biotherapeutics has potent, highly selective binders that we combine into molecular constructs to integrate multiple signals and potentially provide a large therapeutic window, said CSO Alexander Kamb, who co-founded the biotech after a stint as SVP of research at Amgen. They could be antibody and T-cell receptor fragments, according to its statement.

Scott Foraker, his former colleague at the Big Biotech, recently signed on as president and CEO.

Working out of Agoura Hills, California, their team of 40 expects to usher the first product candidate into the clinic next year. Its four programs in development span cancer testis antigen for solid tumors; targets lost antigens for solid tumors; neoantigens for head and neck cancer; and neoantigens for pancreatic, colorectal and lung cancer.

It also plans on constructing a manufacturing facility arguably the most important core competency that differentiates one cell therapy player from another in 2020 with the mindset of ultimately producing its own commercial supply. The site would support an autologous approach, though A2 Bio didnt specify what kind of cells it would use as the source.

Their lead in technical ops is Michelle Kreke, who was credited for leading chemistry, manufacturing and controls for the pioneering CAR-T Yescarta.

Originally posted here:
New cell therapy player launches with $57M from marquee investors to go after 'definitive' tumor targets - Endpoints News

Posted in Cell Therapy | Comments Off on New cell therapy player launches with $57M from marquee investors to go after ‘definitive’ tumor targets – Endpoints News

Page 1,278«..1020..1,2771,2781,2791,280..1,2901,300..»